tradingkey.logo
tradingkey.logo
Search

Medpace Holdings Inc

MEDP
Add to Watchlist
534.720USD
+7.650+1.45%
Close 06/29, 16:00ETQuotes delayed by 15 min
15.27BMarket Cap
32.96P/E TTM

Medpace Holdings Inc

534.720
+7.650+1.45%
View Detailed Chart
TradingKey 图表
Intraday
1m
30m
1h
D
W
M
D

Today

+1.45%

5 Days

+17.35%

1 Month

+19.59%

6 Months

-6.19%

Year to Date

-4.79%

1 Year

+72.11%

Key Figures
530.000Open
540.000High
390.79KVolume
32.96P/E TTM
28.37P/E Dynamic
--Dividend TTM
1.37%Turnover Ratio
527.070Prev. Close
523.060Low
153.75MTurnover
37.68P/E Static
25.46P/B
0.00%Div Yield TTM
22.87%ROA
628.91552wk High
0.98Volume Ratio
404.34MNet Profit
28.49MShares
16.2225EPS TTM
1.19Beta
77.25%ROE
291.28052wk Low
3.21%Amplitude
26.81%Gross Margin
15.27BMarket Cap
8.45Reward/Risk
2.12%Risk Rate

TradingKey Stock Score of Medpace Holdings Inc

Currency: USD Updated: 2026-06-29

Key Insights

Medpace Holdings Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 20 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 440.71.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Medpace Holdings Inc's Score

Industry at a Glance

Industry Ranking
20 / 387
Overall Ranking
67 / 4570
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Medpace Holdings Inc Highlights

StrengthsRisks
Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 34.17% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.53B.
Fairly Valued
The company’s latest PE is 32.96, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 24.53M shares, decreasing 9.12% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 7.08K shares of this stock.

Analyst Rating

Based on 14 analysts
Hold
Current Rating
440.715
Target Price
-16.38%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Medpace Holdings Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Medpace Holdings Inc Info

Medpace Holdings, Inc. is a scientifically driven, global, full-service clinical contract research organization (CRO) providing phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The Company’s operations are principally based in North America, Europe, and Asia.
Ticker SymbolMEDP
CompanyMedpace Holdings Inc
CEOTroendle (August J)
Websitehttps://investor.medpace.com/

FAQs

What is the current price of Medpace Holdings Inc (MEDP)?

The current price of Medpace Holdings Inc (MEDP) is 534.72.

What is the symbol of Medpace Holdings Inc?

The ticker symbol of Medpace Holdings Inc is MEDP.

What is the 52-week high of Medpace Holdings Inc?

The 52-week high of Medpace Holdings Inc is 628.92.

What is the 52-week low of Medpace Holdings Inc?

The 52-week low of Medpace Holdings Inc is 291.28.

What is the market capitalization of Medpace Holdings Inc?

The market capitalization of Medpace Holdings Inc is 15.23B.

Is Medpace Holdings Inc (MEDP) currently rated as Buy, Hold, or Sell?

According to analysts, Medpace Holdings Inc (MEDP) has an overall rating of signal_hold, with a price target of 440.71.

What is the Earnings Per Share (EPS TTM) of Medpace Holdings Inc (MEDP)?

The Earnings Per Share (EPS TTM) of Medpace Holdings Inc (MEDP) is 15.64.
KeyAI